戻る Agendas
STRENGTHENING COLLABORATIVE INNOVATION AND MAXIMISING MUTUAL BENEFIT: PHARMACEUTICAL INDUSTRY PERSPECTIVES
Session Chair(s)
Salah-Dine Chibout
Global Head Discovery & Investigative Safety/Preclinical Safety Therapeutic Area
Novartis Pharma AG, Switzerland
Will PPPs revive breakthrough innovation at the pharmaceutical industry? Cross-private and public partners’ innovation entails distinctive innovation opportunities and challenges because of the heterogeneity between the collaborating parties. Such opportunities and risks will be discussed using the example of IMI with strong and mature PPP networks in key areas of R&D.
Speaker(s)
The U-BIOPRED (Unbiased BIOmarkers in PREDiction of Respiratory Disease Outcomes) Severe Asthma Consortium - An Industry Perspective
Chris Compton, MD
GlaxoSmithKline, United Kingdom
VP, Medicines Development Leader
Experiences from IMI
Matthias Gottwald
Bayer Pharma AG, Germany
Head R&D Policy and Networking
Excellence in RWD: GetReal and its benefit to industry
Melvin Olson, DRSC
Novartis Pharma AG, Switzerland
Head HEOR Excellence